In Pennsylvania, researchers are using genomic profiling to help future treatment of pancreatic cancer, which is the third leading cause of cancer deaths in the United States and has a low survival rate of 8%. One study found a mutation in the anaplastic lymphoma kinase gene and used targeted therapy for the mutated gene. Another study used existing medicines to improve pancreatic cancer outcomes with similar genetic mutations. The key was using the targeted genetic therapy early on as they found patients who had advanced too far with pancreatic cancer did not benefit as much as patients who were in the earlier stages.
Latest article
You better be-leaf it: Dawn Bio cultivates wood in a petri dish
In the Netherlands, a startup based at Wageningen University’s campus is pioneering technology to produce wood from cultured cells.
Dubbed Dawn Bio, the company has...
Algae-based snowboards from WNDR get nod from Time Magazine
In Utah, WNDR Alpine’s algae-based snowboards have been named to Time Magazine’s top 200 inventions list.
Unlike most snowboards, which are made out of petroleum-based...
Prince William’s Earthshot Prize names seaweed firm Coast 4C as a finalist
In Australia, a startup sustainably cultivating seaweed has been chosen as a finalist for Prince William’s 2024 Earthshot Prize.
Coast 4C works with farmers in...